Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status

[1]  M. Rezai,et al.  Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. , 2014, The Lancet. Oncology.

[2]  M. Rezai,et al.  Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): Results from GeparSixto. , 2014 .

[3]  E. Winer,et al.  Identification of biomarkers to predict response to single-agent platinum chemotherapy in metastatic triple-negative breast cancer (mTNBC): Correlative studies from TBCRC009. , 2014 .

[4]  D. Berry,et al.  Abstract S5-01: Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance) , 2013 .

[5]  J. Lubiński,et al.  Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  C. Perou,et al.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Mads Thomassen,et al.  Classifications within Molecular Subtypes Enables Identification of BRCA1/BRCA2 Mutation Carriers by RNA Tumor Profiling , 2013, PloS one.

[8]  C. Perou,et al.  Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. , 2013, The oncologist.

[9]  G. Hortobagyi,et al.  Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations , 2013, Clinical & Experimental Metastasis.

[10]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[11]  J. Lubiński,et al.  Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer , 2012, Breast Cancer Research.

[12]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[13]  Z. Szallasi,et al.  Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. , 2012, Cancer discovery.

[14]  Xi Chen,et al.  TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer , 2012, Cancer informatics.

[15]  L. Bernstein,et al.  Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Funda Meric-Bernstam,et al.  Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Diane D. Liu,et al.  Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations , 2011, Breast Cancer Research and Treatment.

[18]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[19]  A. Tutt,et al.  Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers. , 2011, Cancer discovery.

[20]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[21]  G. Mills,et al.  Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer , 2011, Clinical Cancer Research.

[22]  L. Carey.  Targeted chemotherapy? Platinum in BRCA1-dysfunctional breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Lubiński,et al.  Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[25]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  D. Sgroi,et al.  The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. , 2007, The Journal of clinical investigation.

[27]  C. Perou,et al.  The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.

[28]  C. Deng,et al.  BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution , 2006, Nucleic acids research.

[29]  William D. Foulkes,et al.  Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer , 2004 .

[30]  L. Bégin,et al.  Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. , 2004, Journal of the National Cancer Institute.

[31]  P. J. Welch,et al.  Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.